Cypress Capital’s Cue Biopharma CUE Stock Holding History

Cypress Capital’s Portfolio CUE Stock Details CUE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-24	Closed	-$893	–	148
2024 Q2	$893	Buy	+24	New	+$1.19K	﹤0.01%	333

Other funds holding CUE

Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return

SPC

Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

RSWM

Robertson Stephens Wealth Management San Francisco, California $3.57B AUM 28.36% 1-Year Est. Return

SPC

Sigma Planning Corp Ann Arbor, Michigan $3.6B AUM 24.57% 1-Year Est. Return

GLA

Good Life Advisors Reading, Pennsylvania $1.6B AUM 15.83% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

Cypress Capital's CUE Position: Q3 2024 in Review

Cypress Capital sold out of Cue Biopharma (CUE) in Q3 2024, closing a stake of 24 shares — an estimated $893 sold.

Cypress Capital first reported a position in CUE in Q2 2024 and held it in 1 quarter. The position peaked at $893 in Q2 2024. 50 funds tracked by Wall St. Rank hold CUE as of Q3 2024.

Cypress Capital reported no remaining Cue Biopharma position as of Q3 2024 after selling out during the quarter.
Cypress Capital sold 24 Cue Biopharma shares in Q3 2024, an estimated $893.
Cypress Capital first reported a position in Cue Biopharma in Q2 2024 and held it in 1 quarter.
Cypress Capital's Cue Biopharma position peaked at $893 in Q2 2024.
50 funds tracked by Wall St. Rank held Cue Biopharma as of Q3 2024.

Based on Cypress Capital's 13F filing for Q3 2024, filed 12 Nov 2024.